Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24409069 | 0.94 | RET (0.52) | RET | |
| SCHEMBL24409104 | 0.90 | RET (0.47) | RET | |
| SCHEMBL30630862 | 0.90 | RET (0.47) | RET | |
| SCHEMBL24409237 | 0.87 | RET (0.48) | RET | |
| SCHEMBL24409087 | 0.86 | RET (0.57) | RET | |
| SCHEMBL24409248 | 0.86 | RET (0.52) | RET | |
| SCHEMBL24409224 | 0.86 | RET (0.50) | RET | |
| SCHEMBL24409223 | 0.86 | RET (0.57) | RET | |
| SCHEMBL24409250 | 0.85 | RET (0.52) | RET | |
| SCHEMBL29972619 | 0.85 | RET (0.50) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268897-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4316490-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-116801882-A | Use and method of heterocyclic compounds for treating diseases associated with kinase resistant mutations | 四川科伦博泰生物医药股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2022199503-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | 四川科伦博泰生物医药股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268897-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATING DISEASES RELATED TO KINASE DRUG-RESISTANT MUTATION AND METHOD THEREFOR | RET, VHL, REL | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.